Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

Journal of Immunological Methods

Volumn 409, Issue , 2014, Pages 131-146

  Sarzotti Kelsoe, Marcella ^a   Bailer, Robert T ^b   Turk, Ellen ^b   Lin, Chen li ^b   Bilska, Miroslawa ^a   Greene, Kelli M ^a   Gao, Hongmei ^a   Todd, Christopher A ^a   Ozaki, Daniel A ^a   Seaman, Michael S ^c   Mascola, John R ^b   Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Assay validation; GCLP; HIV; Neutralizing antibody; TZM bl cells

Indexed keywords

DIETHYLAMINOETHYLDEXTRAN; FIREFLY LUCIFERASE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN;

CELL ASSAY; CELL CLONE; CELL COUNT; CELL CULTURE; CLINICAL LABORATORY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; GOOD LABORATORY PRACTICE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTOCOL COMPLIANCE; PSEUDOTYPING; REPORTER GENE; REVIEW; SENSITIVITY AND SPECIFICITY; TZM BL ASSAY; VALIDATION STUDY; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ASSAY VALIDATION; GCLP; HIV; NEUTRALIZING ANTIBODY; TZM-BL CELLS;

ANTIBODIES, NEUTRALIZING; AUTOMATION, LABORATORY; BIOLOGICAL MARKERS; GUIDELINE ADHERENCE; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LIMIT OF DETECTION; NEUTRALIZATION TESTS; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSFECTION;

EID: 84906084946     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.11.022     Document Type: Review

References (27)

1. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
2. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., Alving C.R. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 2007, 81:2087-2091.
3. Choudhry V., Zhang M.Y., Harris I., Sidorov I.A., Vu B., Dimitrov A.S., Fouts T., Dimitrov D.S. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 2006, 348:1107-1115.
4. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., Bouma P., Cham F., Choudhary A., Rybak S.M., Fouts T., Montefiori D.C., Broder C.C., Quinnan G.V., Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007, 363:79-90.
5. Ezzelle J., Rodriguez-Chavez I., Darden J., Stirewalt M., Kunwar N., Hitchcock R., Walter T., D'souza M. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J. Pharm. Biomed. Anal. 2008, 46:18-29.
6. Fenyo E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., Donners H., Heyndrickx L., Alcami J., Bongertz V., Jassoy C., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Sattentau Q., Schuitemaker H., Sutthent R., Wrin T., Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009, 4:e4505.
7. Geonnotti A.R., Bilska M., Yuan X., Ochsenbauer C., Edmonds T.G., Kappes J.C., Liao H.X., Haynes B.F., Montefiori D.C. Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res. Hum. Retrovir. 2010, 26:279-291.
8. Guideline I.H.T. Validation of Analytical Procedures: Text and Methodology Q2 (R1)(2005) Website:. http://www.ich.org/cache/compo/363-272-1.html.
9. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 2005, 79:10103-10107.
10. McLinden R.J., LaBranche C.C., Chenine A.L., Polonis V.R., Eller M.A., Wieczorek L., Ochsenbauer C., Kappes J.C., Perfetto S., Montefiori D.C., Michael N.L., Kim J.H. Detection of HIV-1 neutralizing antibodies in a human CD4+/CXCR4+/CCR5+ T-lymphoblastoid cell assay system. PLoS ONE 2013, 10.1371/journal.pone.0077756.
11. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Virol 2009, vol. 485:395-405. Humana Press. Second edition. G.V.K. Vinayaka, R. Prasad (Eds.).
12. Montefiori D.C., Cornell R.J., Zhou J.Y., Zhou J.T., Hirsch V.M., Johnson P.R. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994, 205:82-92.
13. Montefiori D.C., Karnasuta C., Huang Y., Ahmed H., Gilbert P., de Souza M.S., McLinden R., Tovanabutra S., Laurence-Chenine A., Sanders-Buell E., Moody M.A., Bonsignori M., Ochsenbauer C., Kappes J., Tang H., Greene K., Gao H., LaBranche C.C., Andrews C., Polonis V.R., Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Self S.G., Berman P.W., Francis D., Sinangil F., Lee C., Tartaglia J., Robb M.L., Haynes B.F., Michael N.L., Kim J.H. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 2012, 206:431-441.
14. Montefiori D.C., Robinson W.E., Schuffman S.S., Mitchell W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 1988, 26:231-235.
15. Ozaki D.A., Gao H., Todd C.A., Greene K.M., Montefiori D.C., Sarzotti-Kelsoe M. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS ONE 2012, 7:e30963.
16. Piehler B., Nelson E.K., Eckels J., Ramsay S., Lum K., Wood B., Greene K.M., Gao H.M., Seaman M.S., Montefiori D.C., Igra M. LabKey Server NAb: a tool for analyzing, visualizing and sharing results from neutralizing antibody assays. BMC Immunol. 2011, 12.
17. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol 1998, 72(1998):2855-2864.
18. Platt E.J., Bilska M., Kozak S.L., Kabat D., Montefiori D.C. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 2009, 83:8289-8292.
19. Polonis V.R., Brown B.K., Rosa Borges A., Zolla-Pazner S., Dimitrov D.S., Zhang M.Y., Barnett S.W., Ruprecht R.M., Scarlatti G., Fenyo E.M., Montefiori D.C., McCutchan F.E., Michael N.L. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008, 375:315-320.
20. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4144-4149.
21. Sarzotti-Kelsoe M., Cox J., Cleland N., Denny T., Hural J., Needham L., Ozaki D., Rodriguez-Chavez I.R., Stevens G., Stiles T. Evaluation and recommendations on good clinical laboratory practice guidelines for phase I-III clinical trials. PLoS Med. 2009, 6:e1000067.
22. Sarzotti-Kelsoe M., Bailer R.T., Turk E., Lin C., Bilska M., Greene K.M., Gao H., Todd C.A., Ozaki D.A., Seaman M.S., Mascola J.R., Montefiori D.C. Optimization and Validation of a Neutralizing Antibody Assay for HIV-1 in A3R5 Cells 2014, 409:147-160.
23. Seaman M.S., Janes H., Hawkins N., Grandpre L.E., Devoy C., Giri A., Coffey R.T., Harris L., Wood B., Daniels M.G., Bhattacharya T., Lapedes A., Polonis V.R., McCutchan F.E., Gilbert P.B., Self S.G., Korber B.T., Montefiori D.C., Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010, 84:1439-1452. (in this issue).
24. Stiles T., Grant V., Mawby N. Good Clinical Laboratory Practice (GCLP): A Quality System for Laboratories That Undertake the Analyses of Samples from Clinical Trials. BARQA, Medical Laboratories 2003, 1-18.
25. Takeuchi Y., McClure M.O., Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 2008, 82:12585-12588.
26. Todd C.A., Greene K.M., Yu X., Ozaki D.A., Gao H., Huang Y., Wang M., Li G., Brown R., Wood B., D'Souza M.P., Gilbert P., Montefiori D.C., Sarzotti-Kelsoe M. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J. Immunol. Methods 2012, 375:57-67.
27. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905.